BioSpace News Archive

Cyteir Therapeutics, Inc. today announced that the company will be presenting a poster on the mechanism of action of CYT-0851 at the 34th Annual EORTC-NCI-AACR Symposium at the poster session “Molecular Targeted Agents 1" on Wednesday, October 26, 2022 (Abstract No. 71).

Horizon Therapeutics plc Announces New UPLIZNA ® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2022.

Calidi Biotherapeutics, Inc. today announced a poster presentation highlighting pre-clinical data from the company’s SuperNova1 (SNV1) program at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting, taking place in Boston, Massachusetts and virtually, November 8-12, 2022.

Halberd Corporation (OTC PINK:HALB) demonstrated the removal of Interleukin-6 (IL-6) from human blood serum during in-vitro laboratory studies.

Viridian Therapeutics, Inc. today announced that three abstracts highlighting the potential benefits of VRDN-001 will be presented as oral highlighted and late-breaking poster presentations at the 91st Annual Meeting of the American Thyroid Association (ATA), to be held in Montreal, Canada from October 19 to 23, 2022.

Enveric Biosciences today announced the presentation of results from its lead programs at the 6th International Neurology & Brain Disorders Conference (INBC) to be held on October 24-26, 2022, in Orlando, Florida.

IPA today announced that its subsidiary, Talem Therapeutics LLC (“Talem”), has entered into a multi-target license agreement with OmniAb, Inc., a subsidiary of Ligand Pharmaceuticals Incorporated.

bioAffinity Technologies , Inc., will present results of its research into the use of flow cytometry for analyzing the lung environment to detect diseases of the lung at the American College of Chest Physicians (CHEST) 2022 conference Oct. 16-19, 2022.

Entasis Therapeutics Holdings Inc. announced that six abstracts highlighting sulbactam-durlobactam have been selected for presentation at IDWeek 2022, the annual meeting of the Infectious Disease Society of America taking place October 19-23, 2022 in Washington, D.C.

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today presented data from the Phase 3 PREVENT-19 trial and Study 307 (Lot Consistency) at the World Vaccine Congress Europe 2022.